Stock BXN BIOXYNE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Bioxyne Limited

Equities

BXN

AU000000BXN6

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 04:17:17 03/05/2024 BST 		5-day change 1st Jan Change
0.007 AUD 0.00% Intraday chart for Bioxyne Limited -12.50% -36.36%
04-18 Bioxyne to Raise AU$1.45 Million via Share Issuance MT
02-29 Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Business Summary

Bioxyne Limited is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries Japan, Australia, the United Kingdom, and Czechia. The Company direct sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.

Sales per Business

AUD in Million2022Weight2023Weight Delta
Plant Based
99.1 %
- - 5 99.1 % -
Wholesale
0.8 %
2 93.0 % 0 0.8 % -98.11%
Direct
0.1 %
0 7.0 % 0 0.1 % -98.43%

Sales per region

AUD in Million2022Weight2023Weight Delta
United Kingdom/Europe/Japan
99.1 %
-- 5 99.1 % -
United States
0.8 %
2 80.1 % 0 0.8 % -97.80%
Asia
0.1 %
0 19.9 % 0 0.1 % -99.45%

Managers

Managers TitleAgeSince
Sam Watson CEO
 Chief Executive Officer - 18/05/23
Rachel Qian AUD
 Comptroller/Controller/Auditor - -

Members of the board

Members of the board TitleAgeSince
Peng Ho CHM
 Chairman 65 29/10/12
Jason Hine BRD
 Director/Board Member - 18/05/23
Sam Watson CEO
 Chief Executive Officer - 18/05/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,901,645,398 418,517,125 ( 22.01 %) 0 22.01 %

Shareholders

NameEquities%Valuation
Paramount Star Investments Ltd. (Singapore)
1.893 %
36,000,000 1.893 % 281 880 $

Company contact information

Bioxyne Ltd.

50 Clarence Street Suite 506, Level 5

2000, Sydney

+

http://www.bioxyne.com
address Bioxyne Limited(BXN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOXYNE LIMITED Stock Bioxyne Limited
-36.36% 9.47M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.9B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.7B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BXN Stock
  4. Company Bioxyne Limited